Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial

Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* MONT SAINT-GUIBERT, Belgium – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing...

BioEquity Europe

Novadip Biosciences will be in Dublin, Ireland May 14-16, 2023 for BioEquity Europe. CEO Dr. Denis Dufrane will be hosting meetings.